Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Patten & Patten Inc. TN

Patten & Patten Inc. TN trimmed its position in Becton, Dickinson and Company (NYSE:BDXFree Report) by 3.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,298 shares of the medical instruments supplier’s stock after selling 295 shares during the period. Patten & Patten Inc. TN’s holdings in Becton, Dickinson and Company were worth $2,023,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in BDX. Moneta Group Investment Advisors LLC boosted its holdings in shares of Becton, Dickinson and Company by 95,813.8% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 4,045,643 shares of the medical instruments supplier’s stock worth $1,028,807,000 after purchasing an additional 4,041,425 shares during the last quarter. Norges Bank purchased a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at approximately $697,398,000. Ontario Teachers Pension Plan Board raised its position in shares of Becton, Dickinson and Company by 242.8% during the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,783,769 shares of the medical instruments supplier’s stock valued at $461,158,000 after buying an additional 1,263,391 shares during the period. PineStone Asset Management Inc. raised its position in shares of Becton, Dickinson and Company by 262.0% during the 3rd quarter. PineStone Asset Management Inc. now owns 847,448 shares of the medical instruments supplier’s stock valued at $219,091,000 after buying an additional 613,369 shares during the period. Finally, Marshall Wace LLP raised its position in shares of Becton, Dickinson and Company by 86.6% during the 2nd quarter. Marshall Wace LLP now owns 1,196,061 shares of the medical instruments supplier’s stock valued at $315,772,000 after buying an additional 555,090 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.31% of the stock is currently owned by insiders.

Becton, Dickinson and Company Stock Down 1.2 %

Becton, Dickinson and Company stock opened at $241.02 on Wednesday. Becton, Dickinson and Company has a twelve month low of $229.85 and a twelve month high of $287.32. The stock’s fifty day simple moving average is $239.84 and its 200-day simple moving average is $244.52. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $69.63 billion, a P/E ratio of 57.11, a P/E/G ratio of 2.04 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last issued its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, topping analysts’ consensus estimates of $2.39 by $0.29. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.98 earnings per share. As a group, equities analysts expect that Becton, Dickinson and Company will post 12.94 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 8th were paid a $0.95 dividend. The ex-dividend date of this dividend was Thursday, March 7th. This represents a $3.80 annualized dividend and a yield of 1.58%. Becton, Dickinson and Company’s dividend payout ratio is presently 90.05%.

Analysts Set New Price Targets

Several research firms have recently commented on BDX. Barclays lifted their price target on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a research report on Monday, February 5th. Raymond James boosted their target price on Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $279.17.

Read Our Latest Analysis on BDX

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

See Also

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.